ABC Imagem Cardiovasc. 2026; 39(3): e20260061
First Colombian Experience with Mavacamten in Obstructive Hypertrophic Cardiomyopathy: A Brief Imaging Report
Introduction
Hypertrophic cardiomyopathy (HCM) is a myocardial disease, usually of genetic origin, characterized by increased left ventricular wall thickness unexplained by abnormal loading conditions. Dynamic left ventricular outflow tract (LVOT) obstruction occurs in approximately 70% of patients, either at rest or with provocation, and is closely associated with symptoms and adverse clinical outcomes.,
The relief of the obstructive gradient remains a major therapeutic goal in obstructive HCM. Mavacamten, a cardiac myosin inhibitor, has been shown to reduce LVOT gradients and improve symptoms and functional capacity in symptomatic obstructive HCM., After its regulatory authorization in Colombia in August 2025, mavacamten became a new therapeutic option in this setting.
[…]
5
